Form 8-K

8-K — Endovia Health Sciences, Inc.

Accession: 0001731122-26-001144

Filed: 2026-08-25

Period: 2026-08-24

CIK: 0001553788

SIC: 2080 (BEVERAGES)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — e7891_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (e7891_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: e7891_8k.htm · Sequence: 1

false

0001553788

2026-08-24

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 24, 2026

ENDOVIA

HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Nevada

001-40471

34-1720075

(State or other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

1112 N. Flagler Drive

Fort Lauderdale, Florida

33304

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area

code: (954) 648-7238

Registrant’s Former Name: Splash Beverage

Group, Inc.

Check the appropriate box below if the Form 8-K filing

is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an

emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange

Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark

if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards

provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of

the Act:

Title of Each Class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

EDVA

NYSE American LLC

Item 7.01 Regulation FD Disclosure

On August 25, 2026, Endovia Health Sciences, Inc. formerly known as Splash

Beverage Group, Inc. (the “Company”) issued a press release announcing that it achieved the first FDA Regulatory Milestone

for its CannEpil® veterinary development program under its previously announced collaboration agreement with Lupvindal Biosciences

Ltd., formally initiating the regulatory process for the development of CannEpil® as an investigational veterinary pharmaceutical.

A copy of the press release is furnished as Exhibit

99.1 of this Current Report on Form 8-K.

The information in this Item 7.01 (including Exhibit

99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)

or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of

the Company under the Securities Act of 1933 or the Exchange Act.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit

Description

99.1

Press Release dated August 25, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of

the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

SPLASH BEVERAGE GROUP, INC.

Date: August 25, 2026

By:

/s/ Brady Cobb

Name:

Brady Cobb

Title:

Interim Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: e7891_ex99-1.htm · Sequence: 2

EXHIBIT 99.1

Endovia Health Sciences, formerly Splash Beverage, Achieves First FDA

Regulatory Milestone for CannEpil® Veterinary Development Program

FDA establishes Investigational New Animal Drug (INAD) File No. 14145,

advancing the Company’s companion-animal oncology program and marking first milestone under Lupvindol collaboration

FORT LAUDERDALE, Fla., August 25, 2026 — Endovia Health Sciences,

Inc. (NYSE American: EDVA), formerly Splash Beverage Group, Inc. (NYSE American: SBEV) (“Endovia Health” or the “Company”)

announced that the U.S. Food and Drug Administration’s Center for Veterinary Medicine has established Investigational New Animal

Drug (INAD) File No. 14145 for the Company’s CannEpil® veterinary development program.

The establishment of the INAD file represents the first regulatory milestone

under the Company’s previously announced development and collaboration agreement with Lupvindol Biosciences Ltd. and formally initiates

the FDA regulatory process for the development of CannEpil® as an investigational veterinary pharmaceutical.

Endovia Health is initially pursuing the development of CannEpil® for

the management of cancer-related pain in companion animals, beginning with canine oncology.

Cancer remains the leading cause of death in older dogs, yet there are

currently no FDA-approved therapies specifically indicated for the treatment of cancer-related pain.[1][2]

Veterinarians often rely on off-label treatment approaches that may be limited by gastrointestinal or renal toxicity, sedation, controlled-substance

restrictions or limited clinical evidence. The Company believes this represents a significant unmet medical need within companion-animal

medicine.

The Company intends to pursue development under the FDA’s Minor Use

/ Minor Species (MUMS) designation and Conditional Approval pathway, which is intended to encourage the development of therapies addressing

important unmet veterinary needs.

“This achievement represents much more than an administrative milestone—it

demonstrates our ability to execute,” said Brady Cobb, Chief Executive Officer of Endovia Health Sciences. “When we announced

our collaboration with Lupvindol, we committed to advancing CannEpil through a disciplined, milestone-driven FDA development program.

Receiving our INAD file on schedule validates both our development strategy and the strength of our partnership.”

“In our view, cancer remains one of the greatest unmet medical needs

in companion-animal health. We believe CannEpil has the potential to become an important new therapeutic option, and today’s milestone

officially begins our regulatory engagement with the FDA. Our focus now shifts to finalizing our product development plan, advancing the

required studies and continuing to build a differentiated veterinary pharmaceutical platform.”

Hunter Land, Ph.D., Chief Executive Officer of Lupvindol Biosciences Ltd.,

added:

“Opening the INAD file is the first formal regulatory milestone in

the development process and establishes the framework for our ongoing interactions with the FDA Center for Veterinary Medicine. Our team

has successfully advanced cannabinoid-based medicines through regulated development programs before, and we look forward to applying that

same scientific rigor and regulatory discipline to the CannEpil program as we pursue FDA Conditional Approval.”

[1]

https://en.wikipedia.org/wiki/Cancer_in_dogs

[2]

https://pmc.ncbi.nlm.nih.gov/articles/PMC10352038/

The INAD establishes the regulatory foundation for future FDA interactions,

including development planning, preclinical and clinical studies, manufacturing activities and regulatory submissions supporting potential

Conditional Approval.

The Company expects to provide additional updates as future regulatory

and development milestones are achieved.

About CannEpil®

CannEpil® is a proprietary pharmaceutical-grade cannabinoid formulation

comprised of cannabidiol (CBD) and tetrahydrocannabinol (THC) isolates in an oral liquid formulation manufactured under European Union

Good Manufacturing Practice (EU-GMP) standards. Splash holds the exclusive global rights to develop and commercialize CannEpil® across

licensed fields of use, including veterinary therapeutics.

About Endovia Health Sciences

The Company has rebranded as Endovia Health Sciences (NYSE American:

EDVA), with a corporate name change and ticker symbol change effective on the NYSE American on August 24, 2026. The rebranding reflects

the Company’s evolution into a diversified cannabinoid-based health sciences platform focused on pharmaceutical commercialization,

FDA-regulated human and veterinary therapeutics, and cannabinoid-based consumer wellness and beverage opportunities across pharmaceutical,

veterinary and consumer wellness markets.

Where Science Meets Cannabinoid Innovation

More Information

Endovia Health Sciences: endoviasciences.com

Contact Information

Endovia Health Sciences

investors@endoviasciences.com

Media Contact

Angela Gorman

AMWPR

angela@amwpr.com

917-348-0083

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning

of applicable federal securities laws, including statements regarding the Company’s new strategic focus and corporate name change,

efforts towards the development and commercialization of pharmaceutical products for humans and animals, FDA regulatory activities, international

expansion and future business opportunities. anticipated needs, trends and expectations for the Company’s business and industry

and goals and expectations with respect to the Company’s new business strategy.

Forward-looking statements are based on current expectations and assumptions

and involve risks and uncertainties that could cause actual results to differ materially. These risks include the Company’s ability

to raise the necessary capital to finance the its operations and business and product development plan, satisfy its contractual obligations

including our ability to maintain the license under the license agreement for the CannEpil® product on which the Company’s initial

focus depends and related agreements in connection therewith, our ability to complete required studies, establish product safety and efficacy,

obtain and maintain regulatory authorizations, protect intellectual property and the risk that competitors market the same or similar

products, our ability to execute commercialization or strategic-partnering arrangements, the risk that that the market or demand for any

resulting product we seek to commercialize in the future could be less than expected or projected, our ability to meet our debt obligations

and the negative financial and operational consequences of failing to do so, our ability to comply with NYSE American’s continued

listing standards and the risk that we may be delisted, the possibility that our expectations and perceived benefits with respect to our

business and product development plan and strategic transactions we may pursue prove to be incorrect, and risks with respect to our ability

to negotiate and execute definitive agreements, satisfy closing conditions, obtain required approvals with respect to any such strategic

transaction. There can be no assurance that the Company’s goals and milestones will be achieved, that the Company or its collaborators

will receive or maintain necessary regulatory authorizations or that any initiative will ultimately generate revenue.

Additional risks are described in the Company’s filings with the

Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025 and the Form S-1/A filed

on August 20, 2026. The Company undertakes no obligation to update forward-looking statements except as required by law.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Aug. 24, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 24, 2026

Entity File Number

001-40471

Entity Registrant Name

ENDOVIA

HEALTH SCIENCES, INC.

Entity Central Index Key

0001553788

Entity Tax Identification Number

34-1720075

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1112 N. Flagler Drive

Entity Address, City or Town

Fort Lauderdale

Entity Address, State or Province

Entity Address, Postal Zip Code

33304

City Area Code

(954)

Local Phone Number

648-7238

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par value

Trading Symbol

EDVA

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration